Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
A phase 1/2 trial of SCTB41 in advanced solid tumours, run by Sinocelltech Ltd., now recruiting.
Overview
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. is a phase 1/2 interventional study registered as NCT06600022 by Sinocelltech Ltd., with 441 participants planned, started 2024-10-10 and due to reach its primary completion in 2027-04-30. Interventions recorded: SCTB41.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase I/II Study of SCTB39-1 in Advanced Solid Tumours
Shares Sinocelltech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares SCTB41, Sinocelltech.
- TreatmentSCTB14
Shares Sinocelltech and the tag pipeline.
- TreatmentSCTC21C
Shares Sinocelltech and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.